tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksMarket MoversTipRanks 50 IndexDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA

AKRO Stock Latest News

Akero Therapeutics’ Efruxifermin Study: A Potential Game-Changer for NASH/MASH Treatment
Company AnnouncementsAkero Therapeutics’ Efruxifermin Study: A Potential Game-Changer for NASH/MASH Treatment
13d ago
AKRO
Jefferies sees Akero, Scholar Rock as ‘promising’ takeover targets
PremiumThe Fly
Jefferies sees Akero, Scholar Rock as ‘promising’ takeover targets
26d ago
LLY
MRK
Warner Bros. Discovery to split up, Qualcomm buying Alphawave Semi: Morning Buzz
PremiumThe Fly
Warner Bros. Discovery to split up, Qualcomm buying Alphawave Semi: Morning Buzz
30d ago
CCJ
COE
Akero Therapeutics rumor highlighted in Betaville blog
PremiumThe Fly
Akero Therapeutics rumor highlighted in Betaville blog
1M ago
AKRO
Akero Therapeutics Elects New Directors at Annual Meeting
PremiumCompany Announcements
Akero Therapeutics Elects New Directors at Annual Meeting
1M ago
8K
AKRO
Buy Rating for Akero Therapeutics Driven by EFX’s Promising Position in MASH Treatment and Market Potential
PremiumRatingsBuy Rating for Akero Therapeutics Driven by EFX’s Promising Position in MASH Treatment and Market Potential
1M ago
AKRO
3 Best Stocks to Buy Now, 5/27/2025, According to Top Analysts
Premium
Market News
3 Best Stocks to Buy Now, 5/27/2025, According to Top Analysts
1M ago
UAL
AKRO
Akero Therapeutics price target raised to $64 from $63 at BofA
Premium
The Fly
Akero Therapeutics price target raised to $64 from $63 at BofA
1M ago
AKRO
Biotech Alert: Searches spiking for these stocks today
PremiumThe Fly
Biotech Alert: Searches spiking for these stocks today
2M ago
CVM
TIL
Akero Therapeutics up 16% after Street Insider report on sale being considered
PremiumThe Fly
Akero Therapeutics up 16% after Street Insider report on sale being considered
2M ago
AKRO
Akero Therapeutics exploring potential sale after approach, Street Insider says
PremiumThe Fly
Akero Therapeutics exploring potential sale after approach, Street Insider says
2M ago
AKRO
Akero Therapeutics’ Promising Developments and Financial Strength Support Buy Rating with $73 Price Target
PremiumRatings
Akero Therapeutics’ Promising Developments and Financial Strength Support Buy Rating with $73 Price Target
2M ago
AKRO
Akero Therapeutics price target lowered to $78 from $80 at Citi
PremiumThe FlyAkero Therapeutics price target lowered to $78 from $80 at Citi
2M ago
AKRO
Akero Therapeutics Advances in MASH Treatment Research
Premium
Company Announcements
Akero Therapeutics Advances in MASH Treatment Research
2M ago
AKRO
Akero Therapeutics price target lowered to $84 from $90 at Morgan Stanley
Premium
The Fly
Akero Therapeutics price target lowered to $84 from $90 at Morgan Stanley
2M ago
AKRO
Akero Therapeutics: Strong Financial Health and Promising Clinical Data Justify Buy Rating
PremiumRatings
Akero Therapeutics: Strong Financial Health and Promising Clinical Data Justify Buy Rating
2M ago
AKRO
Akero Therapeutics reports Q1 EPS (90c), consensus (99c)
PremiumThe Fly
Akero Therapeutics reports Q1 EPS (90c), consensus (99c)
2M ago
AKRO
Akero Therapeutics sees cash, equivalents funding operating plan into 2028
PremiumThe Fly
Akero Therapeutics sees cash, equivalents funding operating plan into 2028
2M ago
AKRO
Promising Phase 2b Results for Akero Therapeutics’ Efruxifermin Highlight Potential for FDA Approval Despite Key Risk Score Challenges
PremiumRatings
Promising Phase 2b Results for Akero Therapeutics’ Efruxifermin Highlight Potential for FDA Approval Despite Key Risk Score Challenges
2M ago
AKRO
Promising Phase 2b Results and Future Prospects for Akero Therapeutics’ Efruxifermin Boost Buy Rating
PremiumRatingsPromising Phase 2b Results and Future Prospects for Akero Therapeutics’ Efruxifermin Boost Buy Rating
2M ago
AKRO
Akero Therapeutics announces new analyses of Phase 2b HARMONY trial
Premium
The Fly
Akero Therapeutics announces new analyses of Phase 2b HARMONY trial
2M ago
AKRO
Akero Therapeutics announces publication of Phase 2b SYMMETRY trial
Premium
The Fly
Akero Therapeutics announces publication of Phase 2b SYMMETRY trial
2M ago
AKRO

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >